Monjuvi.com

Site Inspections

Overview & More informations

Monjuvi.com is a website that provides information about the drug Monjuvi, which is used to treat relapsed or refractory acute lymphoblastic leukemia (ALL) in adults. The website includes information about the drug's mechanism of action, clinical trial results, and side effects. It also provides resources for patients and their families, including a patient support program and a financial assistance program.

Monjuvi.com is owned and operated by Loxo Oncology, a biopharmaceutical company that is focused on the development and commercialization of precision oncology therapies. Loxo Oncology was founded in 2013 and is headquartered in Stamford, Connecticut. The company's mission is to improve the lives of patients with cancer by developing and delivering innovative therapies that are targeted to the genetic drivers of their disease.

Monjuvi was approved by the U.S. Food and Drug Administration (FDA) in February 2021. The drug is indicated for the treatment of relapsed or refractory ALL in adults who have a specific genetic mutation called the NUP98-HOXA9 fusion. Monjuvi is a targeted therapy that works by inhibiting the NUP98-HOXA9 fusion protein, which is responsible for the growth and survival of ALL cells.

Monjuvi has been shown to be effective in treating relapsed or refractory ALL. In a clinical trial, 80% of patients who received Monjuvi achieved a complete or partial remission. The median duration of remission was 11.7 months. Monjuvi is generally well-tolerated, with the most common side effects being nausea, vomiting, diarrhea, and fatigue.

Monjuvi is an important new treatment option for patients with relapsed or refractory ALL. The drug is effective, well-tolerated, and provides hope for patients who have exhausted other treatment options.

Domains Expiration Date Updated